Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 3, 2005

View Archived Issues

CPU-86017 enhances BBB permeability as a result of oxidative stress

Depomed and Esprit Pharma enter Proquin XR marketing agreement

MRX-3 improves asthma symptoms in animal studies

First stage of phase II MetXia study completed

Aegis signs new deal for Intravail technology

Phogen and Cancer Research Technology sign agreement for VP22 technology

Harvard and Crucell receive NIH grant for next-generation AdVac vaccines for HIV/AIDS

CE Mark approval for Endeavor drug-eluting stent

WX-671 successfully completes first phase I study

Indevus inlicenses Nebido U.S. rights

Curcumin demonstrates antidepressant-like effects

HX-531 pretreatment improves responses to leptin

In vitro data presented on novel VCAM-1 inhibitor from Novartis

Novel inhibitors of anthrax lethal factor demonstrate significant protection in vivo

Procaine protects against beta-amyloid neurotoxicity in vitro

Orphan drug designation for Large Scale Biology's lysosomal acid lipase

Celebrex approved for ankylosing spondylitis

Japanese approval for Cleactor for acute pulmonary embolism

Final phase I data on the effects and safety of Proellex in uterine fibroids

Therapeutic agents for respiratory and inflammatory disorders in early development

Sevelamer decreases mortality and morbidity of hemodialysis patients

CR-665 shows a promising safety and pharmacokinetic profile in healthy subjects

Novel agents disclosed for the treatment of diabetes and related disorders

Dompe patent claims novel chemokine CXCR1/CXCR2 receptor antagonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...